FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2555988468> ?p ?o ?g. }

• W2555988468 abstract "Background Melanoma cell adhesion molecule (MCAM; CD146) is expressed on the surfaces of a small population of T cells that have the capacity to produce a multitude of cytokines; further, expression of MCAM is a defining characteristic of TH17 cells. As such, MCAM is hypothesized to be central to the pathogenesis of numerous autoimmune disorders, including psoriasis and psoriatic arthritis. Laminin α4 (LAMA4), the primary MCAM ligand, promotes T-cell transmigration into sites of inflammation. Thus, inhibition of MCAM/LAMA4 binding may limit cell infiltration and subsequent pathogenic inflammation. PRX003, a monoclonal antibody designed to bind an MCAM epitope critical for LAMA4 interactions, blocks adhesion of MCAM-expressing cells to LAMA4 rather than targeting an individual cytokine, thus preventing the infiltration of cells responsible for disease pathogenesis. Objectives Study objectives were twofold: (1) to demonstrate preclinical proof of concept for anti-MCAM antibodies in mice overexpressing RAC1, an aggressive transgenic model of psoriasis and (2) to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of PRX003 in healthy human subjects. Methods The effects of anti-MCAM antibodies (murine homolog of PRX003) on the MCAM expression of circulating immune cells and on disease progression were assessed in RAC1 mice treated 3×/week with anti-MCAM antibodies (0.1 or 10 mg/kg) or isotype control from postnatal day 7 (when disease progression is evident) through postnatal day 34. In a first-in-human, randomized, double-blind, placebo-controlled, phase 1, single ascending dose-escalation study (NCT02458677), PRX003 was administered by intravenous infusion over approximately 60 minutes. Five escalating dose cohorts received 0.3, 1.0, 3.0, 10, or 30 mg/kg of PRX003 or placebo (6 subjects randomized to PRX003 and 2 to placebo per cohort) and were subsequently monitored in an inpatient unit for 24 hours and by periodic follow-up for 12 weeks. PD measurements in humans included MCAM expression on circulating T-lymphocytes and serum soluble MCAM. Results Anti-MCAM antibodies demonstrated target-mediated binding to circulating immune cells after administration to RAC1 transgenic mice. Furthermore, anti-MCAM antibody-treated mice experienced marked reductions in MCAM expression levels on circulating cells, resulting in diminished (by 40% to 60%) psoriatic disease progression, as evidenced by less erythema, scaling, and skin thickness than were observed in RAC1 transgenic mice treated with an isotype control antibody. PRX003 may thus have a beneficial impact on inflammatory diseases in humans. Data on the safety, tolerability, serum PRX003 PK, and immunogenicity of PRX003 in healthy human subjects, including PK/PD modeling of markers of target engagement, will be presented for the first time. Conclusions The results of these studies and of previously published reports support further examination of PRX003 in patients with inflammatory disease. A phase 1 multiple ascending dose trial of PRX003 in patients with plaque psoriasis (NCT02630901) is planned. Disclosure of Interest M. Koller Shareholder of: Prothena, Employee of: Prothena, K. Flanagan Shareholder of: Prothena, Employee of: Prothena, M. Skov Shareholder of: Prothena, Employee of: Prothena, R. Goldblum Consultant for: Prothena, Vascular BIogenics Limited, Sophiris, S. Griffith Consultant for: Prothena, R. Barbour Shareholder of: Prothena, Employee of: Prothena, N. Ehsani-Chimeh: None declared, M. Marinkovich: None declared, W. Zago Shareholder of: Prothena, Employee of: Prothena, T. Yednock Shareholder of: Prothena, Consultant for: Prothena, G. Kinney Shareholder of: Prothena, Consultant for: Janssen, Employee of: Prothena, D. Ness Employee of: Prothena" @default.
• W2555988468 created "2016-11-30" @default.
• W2555988468 creator A5000457842 @default.
• W2555988468 creator A5000946009 @default.
• W2555988468 creator A5009919830 @default.
• W2555988468 creator A5015328792 @default.
• W2555988468 creator A5036297287 @default.
• W2555988468 creator A5037725543 @default.
• W2555988468 creator A5054891354 @default.
• W2555988468 creator A5062301909 @default.
• W2555988468 creator A5063444335 @default.
• W2555988468 creator A5071474868 @default.
• W2555988468 creator A5083620898 @default.
• W2555988468 creator A5087237814 @default.
• W2555988468 date "2016-06-01" @default.
• W2555988468 modified "2023-09-26" @default.
• W2555988468 title "OP0205 Clinical and Preclinical Assessment of The Anti-MCAM Monoclonal Antibody PRX003, A Potential Novel Treatment for Th17-Mediated Inflammatory Diseases" @default.
• W2555988468 doi "https://doi.org/10.1136/annrheumdis-2016-eular.3570" @default.
• W2555988468 hasPublicationYear "2016" @default.
• W2555988468 type Work @default.
• W2555988468 sameAs 2555988468 @default.
• W2555988468 citedByCount "0" @default.
• W2555988468 crossrefType "journal-article" @default.
• W2555988468 hasAuthorship W2555988468A5000457842 @default.
• W2555988468 hasAuthorship W2555988468A5000946009 @default.
• W2555988468 hasAuthorship W2555988468A5009919830 @default.
• W2555988468 hasAuthorship W2555988468A5015328792 @default.
• W2555988468 hasAuthorship W2555988468A5036297287 @default.
• W2555988468 hasAuthorship W2555988468A5037725543 @default.
• W2555988468 hasAuthorship W2555988468A5054891354 @default.
• W2555988468 hasAuthorship W2555988468A5062301909 @default.
• W2555988468 hasAuthorship W2555988468A5063444335 @default.
• W2555988468 hasAuthorship W2555988468A5071474868 @default.
• W2555988468 hasAuthorship W2555988468A5083620898 @default.
• W2555988468 hasAuthorship W2555988468A5087237814 @default.
• W2555988468 hasConcept C159654299 @default.
• W2555988468 hasConcept C203014093 @default.
• W2555988468 hasConcept C2776914184 @default.
• W2555988468 hasConcept C542903549 @default.
• W2555988468 hasConcept C71924100 @default.
• W2555988468 hasConcept C8891405 @default.
• W2555988468 hasConceptScore W2555988468C159654299 @default.
• W2555988468 hasConceptScore W2555988468C203014093 @default.
• W2555988468 hasConceptScore W2555988468C2776914184 @default.
• W2555988468 hasConceptScore W2555988468C542903549 @default.
• W2555988468 hasConceptScore W2555988468C71924100 @default.
• W2555988468 hasConceptScore W2555988468C8891405 @default.
• W2555988468 hasLocation W25559884681 @default.
• W2555988468 hasOpenAccess W2555988468 @default.
• W2555988468 hasPrimaryLocation W25559884681 @default.
• W2555988468 hasRelatedWork W1982598880 @default.
• W2555988468 hasRelatedWork W2088128613 @default.
• W2555988468 hasRelatedWork W2166504190 @default.
• W2555988468 hasRelatedWork W2318373157 @default.
• W2555988468 hasRelatedWork W2325054789 @default.
• W2555988468 hasRelatedWork W2333650027 @default.
• W2555988468 hasRelatedWork W2361087302 @default.
• W2555988468 hasRelatedWork W2410291113 @default.
• W2555988468 hasRelatedWork W2631111829 @default.
• W2555988468 hasRelatedWork W2756192987 @default.
• W2555988468 hasRelatedWork W2766965684 @default.
• W2555988468 hasRelatedWork W2791115193 @default.
• W2555988468 hasRelatedWork W2791507797 @default.
• W2555988468 hasRelatedWork W2904895337 @default.
• W2555988468 hasRelatedWork W2936529895 @default.
• W2555988468 hasRelatedWork W2983852549 @default.
• W2555988468 hasRelatedWork W2987386759 @default.
• W2555988468 hasRelatedWork W3098010498 @default.
• W2555988468 hasRelatedWork W3135613518 @default.
• W2555988468 hasRelatedWork W3193121651 @default.
• W2555988468 isParatext "false" @default.
• W2555988468 isRetracted "false" @default.
• W2555988468 magId "2555988468" @default.
• W2555988468 workType "article" @default.